Aflac Incorporated (NYSE: AFL) is a prominent player in the insurance industry, known for its supplemental health insurance products in the U.S. and its leading cancer and medical insurance offerings in Japan. As a Fortune 500 company, Aflac provides financial protection to millions of policyholders, ensuring peace of mind during uncertain times.
On October 8, 2025, Barclays maintained its "Underweight" rating for AFL, while keeping the action as "hold." Despite this, Barclays raised Aflac's price target to $102 from $100. At the time, AFL's stock price was $112.93, reflecting a slight decrease of 0.14, or approximately -0.12%.
Aflac's recent initiative to offer a grace period for premium payments to federal employees affected by the government shutdown highlights its commitment to policyholders. This move is particularly significant for those not receiving pay during this period, showcasing Aflac's dedication to supporting its customers in challenging times.
The stock has traded between $112.55 and $113.89 today, with a market capitalization of approximately $60.4 billion. Over the past year, AFL has seen a high of $115.44 and a low of $96.95, indicating some volatility in its stock performance.
Today's trading volume for AFL on the NYSE is 1,235,775 shares, reflecting investor interest in the company's stock. Despite the "Underweight" rating, Aflac's initiatives and market position continue to make it a significant player in the insurance industry.
